EcoDrugPlus

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPANG00000017600
Gene Symbol: AKT1
5 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPANG00000007275
Gene Symbol: AKT2
4 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 3

Ensembl ID : ENSPANG00000010019
Gene Symbol: AKT3
5 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSPANG00000015024
Gene Symbol: ALK
5 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSPANG00000010459
Gene Symbol: ABCC1
5 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSPANG00000007182
Gene Symbol: ABCC8
5 Cross references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSPANG00000005518
Gene Symbol: ABCC9
4 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSPANG00000012373
Gene Symbol: ATP4A
5 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSPANG00000015119
Gene Symbol: ATP4B
5 Cross references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSPANG00000001212
Gene Symbol: ATP1A1
5 Cross references
322 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSPANG00000013865
Gene Symbol: ATP1A2
5 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSPANG00000002667
Gene Symbol: ATP1A3
5 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).